Hannah Ennerfelt

Hannah Ennerfelt

Auto-generated profile, based on publicly available information

Hannah Ennerfelt

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Cell
Verified
Journal Article
Open access
HEHannah Ennerfelt
Hannah Ennerfelt
EFElizabeth L. Frost
Elizabeth L. Frost
DSDaniel A. Shapiro
Daniel A. Shapiro
CHCoco Holliday
Coco Holliday
KZKristine E. Zengeler
Kristine E. Zengeler
JLJohn Lukens
John Lukens
Recent studies have begun to reveal critical roles for the brain’s professional phagocytes, microglia, and their receptors in the control of neurotoxic amyloid beta (Aβ) and myelin debris accumulation in neurodegenerative disease. However, the critical intracellular molecules that orchestrate neuroprotective functions of microglia remain poorly understood. In our studies, we find that targeted deletion of SYK in microglia leads to exacerbated Aβ deposition, aggravated neuropathology, and cognitive defects in the 5xFAD mouse model of Alzheimer’s disease (AD). Disruption of SYK signaling in this AD model was further shown to impede the development of disease-associated microglia (DAM), alter AKT/GSK3β-signaling, and restrict Aβ phagocytosis by microglia. Conversely, receptor-mediated activation of SYK limits Aβ load. We also found that SYK critically regulates microglial phagocytosis and DAM acquisition in demyelinating disease. Collectively, these results broaden our understanding of the key innate immune signaling molecules that instruct beneficial microglial functions in response to neurotoxic material.

23 August 2024 in Science
Verified
Journal Article
Closed access
PMParas S. Minhas
Paras S. Minhas
JJJeffrey R. Jones
Jeffrey R. Jones
ALAmira Latif-Hernandez
Amira Latif-Hernandez
Yuki SugiuraYuki Sugiura
Yuki Sugiura
ADAarooran S. Durairaj
Aarooran S. Durairaj
KAKatrin I. Andreasson
Katrin I. Andreasson
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor–dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter–dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD.

26 June 2020 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
HEHannah E. Ennerfelt
Hannah E. Ennerfelt
JLJohn Lukens
John Lukens

11 January 2023 in Clinical and Translational Medicine
Verified
Journal Article
Open access
HEHannah Ennerfelt
Hannah Ennerfelt
JLJohn Lukens
John Lukens